This article was originally published on TipRanks.com.
Arena Pharmaceuticals posted a wider-than-expected loss in the fourth quarter, as the biopharmaceutical company’s sales were almost negligible. Shares declined about 2.
The cannabis market is buzzing right now. But the recent rally in cannabis stocks has left some of the bigger names looking overvalued.
It’s a big day for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are shooting up 35% faster than Jack’s magic bean sparking right into a giant beanstalk.
Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) investors have a smile on their faces Monday evening, after the drug maker announced positive Phase 2 results for …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in …
In a research report published Wednesday, FBR analyst Rahul Jasuja reiterated an Outperform rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) with a …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported financial results for the fourth quarter and full-year ended December 31, 2016 and provided a corporate update.